Commercial, field force & R&D view · H1 FY27

Corvexa Pharma

Fictional Indian branded-generics company · 4 therapy areas · 2,140 medical reps · Apr–Sep 2026 · ₹ crore

Sample data · illustrative build by Woodfrog
Market performance

Secondary sales vs market

Monthly secondary sales (stockist to chemist), indexed to April 2025 = 100, against the covered market from audit data. The gap is share gained or lost.

CorvexaCovered marketOutperformance

Market share shift FY25 → H1 FY27

Value share of the covered market against four fictional peers.

Brand portfolio matrix TOP 16 BRANDS

Relative market share (vs the brand's largest competitor) against molecule-market growth. Bubble size is H1 sales. Quadrants follow the growth-share logic used in brand planning.

Patient & prescription flow H1 · '000 PATIENTS

From diagnosis to persistent therapy for the selected therapy area. Hover a band to see the drop-off.

Field force effectiveness

Call coverage by region and doctor decile % OF TARGET HCPs MET 2+ TIMES

Doctors are ranked into deciles by prescription potential (D10 = highest). Coverage should rise with decile; cells below 60% are flagged.

Reach and frequency by decile LAST 90 DAYS

Bars show the share of each decile reached; the line is average calls per reached doctor. The plan is 3+ calls a month for D8 to D10.

Reach %Calls per HCP
Clinical development

Clinical & regulatory pipeline CY2025 – CY2028

Each programme by phase, with milestones: ◆ first patient in, ● database lock, ▲ regulatory filing. The vertical line is today.

Enrolment burn-up

Cumulative patients randomised against plan, across active sites.

Quality & supply

Batch release performance LAST 12 MONTHS

Bars: median days from manufacture to QA release. Line: right-first-time batches (no deviation or rework). Target 95%.

Release cycle (days)Right first time

Cold-chain excursions

Temperature-logger alerts on 2–8 °C shipments by distribution lane over the last 90 days. Size is minutes outside range; red means stock was quarantined.

Demonstration build. Corvexa Pharma, its brands, competitors, trials and every figure are synthetic, modelled on Indian pharma commercial patterns (stockist secondary sales, prescription audits, doctor deciling, CDSCO filing timelines, Schedule M quality norms). Built by Woodfrog on SFA call logs, distributor sales, CTMS and QMS data, joined at brand, territory and week grain.